The American College of Clinical Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education with Commendation.
The American College of Clinical Pharmacy and the American Society of Health-System Pharmacists are approved by BPS as a provider for the recertification of of BCOP.
BPS is an autonomous division of the American Pharmacists Association. To maintain its strict, independent standards for certification, BPS does NOT endorse or provide review information, preparatory courses, or study guides for board certification examinations. BPS, through its specialty councils, is responsible for specialty examination content, administration, scoring, and all other aspects of its certification programs. BPS is totally separate and distinct from ACCP. For information about BPS specialty recertification the BPS recertification process, go to: www.bpsweb.org/
To receive recertification credit, posttests must be submitted prior to the recertification posttest deadline (see above). Only completed tests are eligible for credit; no partial or incomplete tests will be processed. You may complete one or all available posttests for credit.
The passing point to earn recertification credit is based on an expert analysis of the assessment items in each posttest. Any posttest submitted before the recertification test deadline that meets this passing point will earn recertification credits. These credits will be assigned as of the date of test submission and reported within 48 hours to BPS. For statements of recertification credit, visit www.bpsweb.org.
In accordance with BPS guidelines concerning remediation for products launched in 2024 and after, posttests that do not reach the passing point for recertification credit will generate a second-chance test option. This test will automatically appear in the learner’s My Account page and will have assessment items presented in a different order. To qualify for recertification credit, the second-chance test must be submitted before the recertification deadline stated above.
The ACCP Recertification Dashboard is a free online tool that can track recertification credits as they are earned through ACCP and schedule new opportunities for credits from upcoming ACCP professional development programs. Questions regarding the number of hours required for recertification should be directed to BPS at www.bpsweb.org.
Target Audience: These recertification activities are intended for board certified pharmacists seeking to update their knowledge and skills in:
Adult Sarcomas
Bladder, Renal, Testicular Cancer
Breast Cancer
Gynecologic Malignancies
Hematopoietic Cell Transplantation
Lung Cancer
Lymphomas
Melanoma and Non-Melanoma Skin Cancers
Multiple Myeloma
Oncology Practice Management
Pediatric Malignancies and Supportive Care
Pharmacogenomics in Oncology
Research Design, Statistics, and Evaluating Oncology Literature
Module A: Hematopoietic Cell Transplantation, Multiple Myeloma, Pediatric Malignancies and Supportive Care Activity Number: 0204-9999-24-952-H01-P Contact Hour(s): 4.00 Activity Type: Application Based Learning ObjectivesBolaños-Meade J, Hamadani M, Wu J et al. Post-transplantation cyclophosphamide-based graft-versushost disease prophylaxis. N Engl J Med. 2023;388(25):2338-2348.
Learning Objectives:
- Describe the study of posttransplant cyclophosphamide for graft-vs.-host disease (GVHD) prophylaxis in allogeneic hematopoietic cell transplantation.
- Develop recommendations for the use of posttransplant cyclophosphamide in allogeneic hematopoietic cell transplantation for the prevention of GVHD.
- Select appropriate patients to receive posttransplant cyclophosphamide according to the results of the BMT CTN 1703 trial.
Sonneveld P, Dimopoulos MA, Boccadoro M et al. Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2023. 2024; 390:301-313.
Learning Objectives:
- Describe the PERSEUS study evaluating the addition of daratumumab to bortezomib, lenalidomide, and dexamethasone (VRd) versus VRd for the treatment of newly diagnosed multiple myeloma.
- Develop recommendations for the use of daratumumab-VRd for the treatment of newly diagnosed multiple myeloma.
- Select appropriate patients to receive daratumumab-VRd according to the results of the PERSEUS study.
Maese L, Loh ML, Choi MR et al. Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study. Blood. 2023;141(7): 704-712.
Learning Objectives:
- Describe the study of recombinant Erwinia asparaginase for acute lymphoblastic leukemia (ALL).
- Develop recommendations for the use of recombinant Erwinia asparaginase in patients with ALL.
- Select appropriate patients to receive recombinant Erwinia asparaginase therapy according to the results of the study by Maese et al.
|
Module B: Oncology Practice Management, Lung Cancer, Breast Cancer, Adult Sarcomas Activity Number: 0204-9999-24-953-H01-P Contact Hour(s): 4.00 Activity Type: Application Based Learning ObjectivesSantos ES, Oliver TK, Lacchetti C et al. Drug shortages in oncology: ASCO clinical guidance for alternative treatments. JCO Oncol Pract. 2023;20:19-32.
Learning Objectives:
- Describe the clinical practice guidelines from the American Society of Clinical Oncology (ASCO) to navigate the disruption in antineoplastic drug supply caused by drug shortages in patients with cancer.
- Develop recommendations for the use of institutional strategies to manage drug shortages with anticancer treatment regimens in patients with cancer.
- Select appropriate patients to receive modified antineoplastic treatment regimens according to the ASCO guidelines for drug shortages in oncology.
Passaro A, Wang J, Wang Y et al. Amivantamab plus chemotherapy with and without lazertinib in EGFRmutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol. 2023;35: 77-90.
Learning Objectives:
- Describe the MARIPOSA-2 trial of amivantamab plus chemotherapy with or without lazertinib for patients with advanced non–small cell lung cancer.
- Develop recommendations for the use of amivantamab plus chemotherapy with or without lazertinib in patients with advanced non–small cell lung cancer given the results of the MARIPOSA-2 trial.
- Select appropriate patients to receive amivantamab plus chemotherapy with or without lazertinib given the results of the MARIPOSA-2 trial.
Moy B, Wolff, AC, Rumble RB et al. Chemotherapy and targeted therapy for endocrine-pretreated or hormone receptor-negative metastatic breast cancer and human epidermal growth factor receptor 2 testing in breast cancer: ASCO Guideline Rapid Recommendation Update Q and A. JCO Oncol Pract. 2023;19:547-550.
Learning Objectives:
- Describe the clinical practice guideline from ASCO for the use of sacituzumab govitecan and trastuzumab deruxtecan in the management of endocrine-pretreated or hormone receptornegative metastatic breast cancer.
- Develop recommendations for the use of sacituzumab govitecan and trastuzumab deruxtecan in patients with endocrine-pretreated or hormone receptor–negative metastatic breast cancer.
- Select appropriate patients to receive sacituzumab govitecan and trastuzumab deruxtecan according to the ASCO guideline rapid recommendation update Q and A.
McCabe C, Wright H, Polson K, Wagner AJ. Supporting patients in the transition to the revised pexidartinib dosing regimen: perspectives from the multidisciplinary clinical and allied health 2 professional team. Orphanet J Rare Dis. 2023;18(1):313.
Learning Objectives:
- Develop patient education strategies to communicate the importance of adhering to the revised pexidartinib dosing regimen, including the low-fat meal requirement.
- Design a multidisciplinary plan to educate patients about how to minimize potential adverse effects.
- Develop patient education strategies that emphasize the importance of adherence to the Risk Evaluation and Mitigation Strategy (REMS) program, including regular liver function monitoring.
|
Module C: Bladder, Renal Cell, and Testicular Cancers; Gynecologic Malignancies; Pharmacogenomics in Oncology Activity Number: 0204-9999-24-954-H01-P Contact Hour(s): 4.00 Activity Type: Application Based Learning ObjectivesLoriot Y, Matsubara N, Park SH et al. Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N Engl J Med. 2023;389:1961-71.
Learning Objectives:
- Describe the study by Loriot et al. of erdafitinib compared with chemotherapy for advanced or metastatic urothelial carcinoma.
- Develop recommendations for the use of erdafitinib in patients with advanced or metastatic urothelial carcinoma.
- Select appropriate patients to receive erdafitinib according to the results of THOR cohort 1 by Loriot et al.
Eskander RN, Sill MW, Beffa L et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med. 2023;388(23):2159-2170.
Learning Objectives:
- Describe the study of pembrolizumab in combination with chemotherapy for advanced or recurrent endometrial cancer.
- Develop recommendations for the use of pembrolizumab in combination with chemotherapy in patients with advanced or recurrent endometrial cancer.
- Select appropriate patients to receive pembrolizumab in combination with chemotherapy according to the results of NRG-GY018.
Hertz DL. Assessment of the clinical utility of pre-treatment DPYD testing for patients receiving fluoropyrimidine chemotherapy. J Clin Oncol. 2022;40:3882-92.
Baker SD, Bates SE, Brooks GA et al. DPYD testing: time to put patient safety first. J Clin Oncol. 2023;41:2701-2705.
Learning Objectives:
- Describe the role of DPYD testing for patients receiving fluoropyrimidine therapy.
- Develop recommendations for the use of fluoropyrimidines in patients with different DPYD genotypes.
- Select appropriate patients to receive fluorouracil and capecitabine according to the results of DPYD
|
Module D: Melanoma and Non-Melanoma Skin Cancers; Lymphomas; Research Design, Statistics, and Evaluating Oncology Literature Activity Number: 0204-9999-24-955-H01-P Contact Hour(s): 4.00 Activity Type: Application Based Learning ObjectivesAtkins MB, Lee SJ, Chmielowski B et al. Combination dabrafenib and trametinib versus combination nivoluma and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trialECOG-ACRIN EA613. J Clin Oncol. 2022 Sept 20; 41(2):186-197.
Learning Objectives:
- Apply the outcomes of the Atkins et al. trial to patients with melanoma whose treatment plan includes anti–programmed cell death protein 1/cytotoxic T-cell lymphocyte-4 (PD-1/CTLA-4) or BRAF/MEK therapy.
- Summarize the strengths and weaknesses of the design and methods used in the Atkins et al. trial.
- Counsel patients with advanced melanoma on the long-term outcomes of immune checkpoint inhibitor or BRAF/MEK therapy.
Abramson JS, Solomon SR, Arnason J et al. Lisocabtagene maraleucel as second-line therapy for large Bcell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023;141(14):1675-1684.
Learning Objectives:
- Describe the TRANSFORM study of lisocabtagene maraleucel versus the standard of care for the second-line treatment of relapsed or refractory large B-cell lymphoma.
- Develop recommendations for the use of lisocabtagene maraleucel for the second-line treatment of diffuse large B-cell lymphoma.
Hunter D, Holmes C. Where medical statistics meets artificial intelligence. N Engl J Med. 2023; 389:1211-1219.
Eskander R, Sill M, Beffa L et al. Pembrolizumab plus chemotherapy in advanced endometrial cancer. N Engl J Med. 2023:388:2159-2170.
Learning Objectives:
- Describe ways in which artificial intelligence (AI) might be used to enhance oncology clinical trials.
- Interpret an oncology clinical trial evaluating nivolumab in combination for a patient with advanced urothelial carcinoma.
- Develop a plan to incorporate AI into an oncology clinical trial evaluating nivolumab in combination for advanced urothelial carcinoma.
|
The American College of Clinical Pharmacy does not solicit or accept external commercial/financial support for its continuing pharmacy education activities. No commercial/financial support has been solicited or accepted for this activity.